共 50 条
- [1] IK-930 is a novel TEAD inhibitor for the treatment of cancers harboring mutations in the Hippo signal transduction pathwayCANCER RESEARCH, 2022, 82 (12)Amidon, Benjamin S.Sanchez-Martin, MartaBartolini, WilminSyed, SakeenaMcGovern, KarenXu, LanEcsedy, JeffreyZhang, X. MichelleConstan, AlexCastro, Alfredo C.
- [2] A phase 1, dose-escalation, first-in-human study of ARQ 087, an oral pan-FGFR inhibitor, in adult subjects with advanced solid tumorsEUROPEAN JOURNAL OF CANCER, 2014, 50 : 125 - 125Papadopoulos, K.Tolcher, A.Kittaneh, M.Patniak, A.Rasco, D.Chambers, G.Newth, G.Savage, R.Hall, T.Schwartz, B.Kazakin, J.LoRusso, P.
- [3] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumorsInvestigational New Drugs, 2019, 37 : 674 - 683Elena ElezCarlos Gomez-RocaArturo Soto Matos-PitaGuillem ArgilesThibaud ValentinCinthya CoronadoJorge IglesiasTeresa MacarullaSarah BetrianSalvador FudioKatrin ZaragozaJosep TaberneroJean-Pierre Delord
- [4] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumorsINVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 674 - 683Elez, ElenaGomez-Roca, CarlosSoto Matos-Pita, ArturoArgiles, GuillemValentin, ThibaudCoronado, CinthyaIglesias, JorgeMacarulla, TeresaBetrian, SarahFudio, SalvadorZaragoza, KatrinTabernero, JosepDelord, Jean-Pierre
- [5] First-in-human phase 1 dose-escalation study of DS-6051b, an oral ROS1 and NTRK inhibitor, in subjects with advanced solid tumorsCANCER RESEARCH, 2016, 76Papadopoulos, Kyriakos P.Borazanci, ErkutVon Hoff, DanielGandhi, LeenaPatnaik, AmitaTachibana, MasayaZahir, HamimGajee, RoohiGoldberg, TernSenaldi, GiorgioOu, Sai-Hong
- [6] First-in-human study of oral S 49076, a MET/AXL/FGFR inhibitor, in advanced solid tumorsANNALS OF ONCOLOGY, 2015, 26 : 37 - 37Postel-Vinay, S.Hollebecque, A.Soria, J. -C.Balandraud, S.Brendel, K.Cattan, V.Jacquet-Bescond, A.Busto, N. LopezMalasse, S.Marfai, L.Pauly, J.Prudkin, L.Azaro, A.Rodon, J.
- [7] A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumorsONCOTARGET, 2015, 6 (21) : 18693 - 18706Hong, David S.Rosen, PeterLockhart, A. CraigFu, SiqingJanku, FilipKurzrock, RazelleKhan, RabiaAmore, BennyCaudillo, IsaacDeng, HongjieHwang, Yuying C.Loberg, RobertNgarmchamnanrith, GatareeBeaupre, Darrin M.Lee, Peter
- [8] First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2013, 19 (19) : 5494 - 5504Brunetto, Andre T.Ang, Joo ErnLal, RohitOlmos, DavidMolife, L. RhodaKristeleit, RebeccaParker, AnnCasamayor, IsabelOlaleye, MuyibatMais, AnnaHauns, BernhardStrobel, VeraHentsch, Berndde Bono, Johann S.
- [9] A first-in-human, phase 1 study evaluating oral TACC3 inhibitor, AO-252, in advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Dumbrava, Ecaterina ElenaKennon, Amber MichelleBalema, Wintana A.Lim, ChaeminVempati, SridharStergiopoulos, SotiriosRichardson, Debra L.
- [10] A first-in-human, phase I study of an oral hedgehog pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumorsMOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)Siu, Lillian L.Papadopoulos, Kyriakos P.Alberts, Steven R.Taylor, SaraPatnaik, AmitaChen, Eric X.Tolcher, AnthonyVakkalaguada, BlisseLang, LixinAhlers, ChristophBennett, Kelly L.Van Tornout, Jan M.